Global healthcare company Abbott have announced further investment of €37.8m in its cardiovascular Research and Development Centre based at its Vascular devices site in Clonmel, Co. Tipperary.
Abbott is the world leader in drug-eluting stents. R&D and manufacturing of Abbott’s new vascular technologies to treat complex heart disease take place at its Clonmel site.
The continued major investment programme in its R&D centre in Clonmel, supported by the Irish government through IDA Ireland, comes as Abbott celebrates 75 years in Ireland this year. Over the next three years Abbott will invest €37.8 million in an R&D programme focusing on the discovery, innovation and development of a number of projects, these include next generation drug eluting stents, as well as coronary and endovascular balloon technologies.
Deirdre Mullins, Site Director, Abbott Clonmel stated:
“Our market leading XIENCE stents were developed in Clonmel and today’s announcement places us at the vanguard of Abbott’s global research efforts in cardiovascular treatments. We are very proud that the life changing technologies we design and manufacture in Clonmel are saving lives in Ireland and across the world.”
Dr Diarmuid Meagher, Director of Research and Development, Abbott, explains:
“We adapted the XIENCE design to develop a stent for older and more complex patients which was smaller, more flexible and physically stronger. Its sophisticated navigation makes it easier to manoeuvre through challenged arteries and obstacles and it’s now being used in 90 countries around the world.”
Source: Ireland South East
